You are here

Article Text

Article menu
Download PDFPDF
Case Reports: Novel treatment (new drug/interventions; established drug/procedure in new situation)
Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan
  1. Karen M Yun and
  2. Lyudmila Bazhenova
  1. Division of Hematology-Oncology, Moores Cancer Center at UC San Diego Health, La Jolla, California, USA
  1. Correspondence to Dr Karen M Yun; k5yun{at}health.ucsd.edu

Abstract

Human epidermal growth factor receptor 2 (HER2) alterations can occur as gene mutations, gene amplification or protein overexpression. DESTINY-Lung01 and DESTINY-Lung02 demonstrated the efficacy of trastuzumab deruxtecan in the subsequent line setting in patients with unresectable or metastatic HER2-mutated non-small-cell lung cancer (NSCLC). Trastuzumab deruxtecan has not been studied in select patients with HER2-amplified NSCLC. Here, we present the first reported case of metastatic HER2-amplified NSCLC treated with trastuzumab deruxtecan with a durable response to therapy.

  • Lung cancer (oncology)
  • Therapeutic indications

http://dx.doi.org/10.1136/bcr-2022-253260

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors The following authors were responsible for drafting of the text, sourcing and editing of clinical images, investigation results, drawing original diagrams and algorithms, and critical revision for important intellectual content: KMY and LB. KMY was responsible for drafting the original text, reviewed and edited the final version of the manuscript, and drafted and edited the figures. LB was responsible for the conceptualization of this case report and reviewed and edited the final version of the manuscript.The following authors gave final approval of the manuscript: KMY and LB.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

    • Competing interests KMY has no competing interests. LAB reports consulting fees from Abbvie, Bayer, Daiichi Sankyo, Elevation Oncology, Genentech/Roche, InterVenn Biosciences, Johnson and Johnson, Merck, Mirati Therapeutics, Neuvogen, Novocure, ORIC, Regeneron, Sanofi, and Turning Point Therapeutics and owns stock/shares in Epic Sciences.

    • Provenance and peer review Not commissioned; externally peer reviewed.